Strange: Bullish HALO Analysts Actually See -16.88% Downside
December 21, 2020 at 09:04 AM EST
Analyst ratings can sometimes be complicated, and we here at ETF Channel have noticed a bit of a paradox with Halozyme Therapeutics Inc (HALO). The average 12-month price target for HALO — averaging the work of 12 analysts — reveals an average price target of $35.67/share..